 |
市場調查報告書
商品編碼
1892752
血糖儀市場機會、成長促進因素、產業趨勢分析及預測（2026-2035年）Glucometer Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2026 - 2035 |
||||||
2025年全球血糖儀市值為340億美元，預計2035年將以13%的複合年成長率成長至1137億美元。
由於糖尿病盛行率不斷上升，以及自我血糖監測（SMBG）在有效疾病管理中的重要性日益凸顯，市場正在不斷擴張。全球醫療保健系統正面臨來自慢性病、人口老化以及提供經濟高效醫療服務的巨大壓力，這使得血糖儀成為增強患者自主權和改善臨床療效的關鍵工具。現代血糖儀的功能已不再局限於簡單的血糖測量，而是融合了藍牙連接、行動應用程式整合和雲端資料共享等功能。這些進步實現了即時監測、遠距會診和數據驅動的決策，使患者能夠積極管理自身病情，臨床醫生也能更有效率地制定個人化治療方案，從而革新了糖尿病照護模式。與遠距醫療和數位健康生態系統的整合進一步增強了全球範圍內的患者參與度和慢性病管理能力。
| 市場範圍 | |
|---|---|
| 起始年份 | 2025 |
| 預測年份 | 2026-2035 |
| 起始值 | 340億美元 |
| 預測值 | 1137億美元 |
| 複合年成長率 | 13% |
到 2025 年，自我監測血糖儀市佔率將達到 63.5%。 SMBG 設備仍被患者廣泛用於家庭監測，減少了對頻繁就診的依賴，並允許及時干預以更好地控制病情。
2025年，第2型糖尿病市場佔比將達到69.2%，預計未來將持續成長。全球第2型糖尿病負擔持續加重，支撐了該領域對血糖儀的持續需求。
預計到2025年，美國血糖儀市場規模將達到130億美元，顯示該市場已趨於成熟且技術先進。強大的醫療基礎設施、廣泛的保險覆蓋、高糖尿病盛行率以及包括遠距醫療和遠距患者監測在內的數位化醫療解決方案的快速普及，都推動了市場成長。這些因素加速了血糖儀在常規臨床實踐和居家護理中的應用。
目錄
第1章：方法論與範圍
第2章：執行概要
第3章：行業洞察
- 產業生態系分析
- 供應商格局
- 影響價值鏈的因素
- 產業影響因素
- 成長促進因素
- 全球糖尿病盛行率不斷上升
- 血糖儀的技術進步
- 全球對自我監測設備的需求不斷成長
- 政府為提高民眾意識所採取的舉措
- 產業陷阱與挑戰
- 先進設備和配件價格昂貴
- 缺乏報銷機制和嚴格的監管
- 市場機遇
- 將血糖儀與數位健康生態系統整合
- 成長促進因素
- 成長潛力分析
- 監管環境
- 北美洲
- 歐洲
- 亞太地區
- 技術格局
- 當前技術趨勢
- 新興技術
- 未來市場趨勢
- 專利分析
- 波特的分析
- PESTEL 分析
第4章：競爭格局
- 介紹
- 公司市佔率分析
- 全球的
- 北美洲
- 歐洲
- 公司矩陣分析
- 主要市場參與者的競爭分析
- 競爭定位矩陣
- 關鍵進展
- 併購
- 夥伴關係與合作
- 新產品發布
- 擴張計劃
第5章：市場估算與預測：依產品類型分類，2022-2035年
- 自我監測血糖儀
- 連續血糖監測儀
第6章：市場估算與預測：依應用領域分類，2022-2035年
- 1型糖尿病
- 2型糖尿病
- 妊娠糖尿病
第7章：市場估算與預測：依配銷通路分類，2022-2035年
- 醫院藥房
- 零售藥局
- 線上銷售
- 糖尿病診所和中心
第8章：市場估算與預測：依地區分類，2022-2035年
- 北美洲
- 美國
- 加拿大
- 歐洲
- 德國
- 英國
- 法國
- 西班牙
- 義大利
- 荷蘭
- 亞太地區
- 中國
- 印度
- 日本
- 澳洲
- 韓國
- 拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 中東和非洲
- 南非
- 沙烏地阿拉伯
- 阿拉伯聯合大公國
第9章：公司簡介
- Abbott Laboratories
- AgaMatrix
- All Medicus
- Arkray,
- Ascensia Diabetes Care Holdings
- B. Braun Melsungen
- Bionime Corporation
- DarioHealth Corporation
- Dexcom
- Essenlife Bioscience
- F. Hoffmann-La Roche
- LifeScan
- Medtronic
- Nova Biomedical
- Sinocare
The Global Glucometer Market was valued at USD 34 billion in 2025 and is estimated to grow at a CAGR of 13% to reach USD 113.7 billion by 2035.
The market is expanding due to the rising prevalence of diabetes and the increasing importance of self-monitoring of blood glucose (SMBG) for effective disease management. Healthcare systems worldwide are facing growing pressure from chronic illnesses, aging populations, and the need to deliver cost-efficient care, making glucometers a vital tool for patient empowerment and improved clinical outcomes. Modern glucometers are moving beyond simple glucose measurement, incorporating features such as Bluetooth connectivity, mobile app integration, and cloud-based data sharing. These advancements enable real-time monitoring, remote consultations, and data-driven decision-making, transforming diabetes care by allowing patients to actively manage their condition and clinicians to tailor personalized treatment strategies efficiently. Integration with telehealth and digital health ecosystems further strengthens patient engagement and chronic disease management capabilities globally.
| Market Scope | |
|---|---|
| Start Year | 2025 |
| Forecast Year | 2026-2035 |
| Start Value | $34 Billion |
| Forecast Value | $113.7 Billion |
| CAGR | 13% |
The self-monitoring blood glucose meters segment held a 63.5% share in 2025. SMBG devices remain widely used by patients for home-based monitoring, reducing dependency on frequent clinical visits and allowing timely interventions for better disease control.
The type 2 diabetes segment accounted for a 69.2% share in 2025 and is expected to grow further. The global burden of type 2 diabetes continues to increase, supporting sustained demand for glucometers in this segment.
U.S. Glucometer Market was valued at USD 13 billion in 2025, representing a mature and technologically advanced market. Growth is fueled by strong healthcare infrastructure, widespread insurance coverage, high diabetes prevalence, and rapid adoption of digital health solutions, including telehealth and remote patient monitoring. These factors accelerate the integration of glucometers into routine clinical practice and home-based care.
Key players in the Global Glucometer Market include Arkray, Bionime Corporation, Dexcom, DarioHealth Corporation, Nova Biomedical, Abbott Laboratories, All Medicus, Ascensia Diabetes Care Holdings, F. Hoffmann-La Roche, LifeScan, Medtronic, AgaMatrix, Essenlife Bioscience, B. Braun Melsungen, and Sinocare. Companies in the Global Glucometer Market are strengthening their presence through continuous innovation in device technology, such as integrating mobile connectivity, AI-driven analytics, and cloud platforms to enhance patient engagement and data accessibility. Strategic partnerships with healthcare providers and telehealth platforms help expand market reach and enable recurring usage. Firms are also investing in global distribution networks and after-sales support to improve accessibility and customer satisfaction.
Table of Contents
Chapter 1 Methodology and Scope
- 1.1 Market scope and definition
- 1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
- 1.3 Data mining sources
- 1.3.1 Global
- 1.3.2 Regional/country
- 1.4 Base estimates and calculations
- 1.4.1 Base year calculation
- 1.4.2 Key trends for market estimation
- 1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.6 Forecast model
- 1.7 Research assumptions and limitations
Chapter 2 Executive Summary
- 2.1 Industry 360° synopsis
- 2.2 Key market trends
- 2.2.1 Regional trends
- 2.2.2 Product type trends
- 2.2.3 Application trends
- 2.2.4 Distribution channel trends
- 2.3 CXO perspectives: Strategic imperatives
- 2.3.1 Key decision points for industry executives
- 2.3.2 Critical success factors for market players
- 2.4 Future outlook and strategic recommendations
Chapter 3 Industry Insights
- 3.1 Industry ecosystem analysis
- 3.1.1 Supplier landscape
- 3.1.2 Factors affecting the value chain
- 3.2 Industry impact forces
- 3.2.1 Growth drivers
- 3.2.1.1 Rising prevalence of diabetes worldwide
- 3.2.1.2 Technological advancements in glucometer
- 3.2.1.3 Rising demand for self-monitoring devices globally
- 3.2.1.4 Government initiatives for increasing awareness among people
- 3.2.2 Industry pitfalls and challenges
- 3.2.2.1 High cost of advanced devices and accessories
- 3.2.2.2 Lack of reimbursement and stringent regulations
- 3.2.3 Market opportunities
- 3.2.3.1 Integration of glucometers with digital health ecosystems
- 3.2.1 Growth drivers
- 3.3 Growth potential analysis
- 3.4 Regulatory landscape
- 3.4.1 North America
- 3.4.2 Europe
- 3.4.3 Asia Pacific
- 3.5 Technology landscape
- 3.5.1 Current technological trends
- 3.5.2 Emerging technologies
- 3.6 Future market trends
- 3.7 Patent analysis
- 3.8 Porter's analysis
- 3.9 PESTEL analysis
Chapter 4 Competitive Landscape, 2025
- 4.1 Introduction
- 4.2 Company market share analysis
- 4.2.1 Global
- 4.2.2 North America
- 4.2.3 Europe
- 4.3 Company matrix analysis
- 4.4 Competitive analysis of major market players
- 4.5 Competitive positioning matrix
- 4.6 Key developments
- 4.6.1 Merger and acquisition
- 4.6.2 Partnership and collaboration
- 4.6.3 New product launches
- 4.6.4 Expansion plans
Chapter 5 Market Estimates and Forecast, By Product Type, 2022 - 2035 ($ Mn)
- 5.1 Key trends
- 5.2 Self-monitoring blood glucose meters
- 5.3 Continuous glucose monitors
Chapter 6 Market Estimates and Forecast, By Application, 2022 - 2035 ($ Mn)
- 6.1 Key trends
- 6.2 Type 1 diabetes
- 6.3 Type 2 diabetes
- 6.4 Gestational diabetes
Chapter 7 Market Estimates and Forecast, By Distribution Channel, 2022 - 2035 ($ Mn)
- 7.1 Key trends
- 7.2 Hospital pharmacies
- 7.3 Retail pharmacies
- 7.4 Online sales
- 7.5 Diabetes clinics and centers
Chapter 8 Market Estimates and Forecast, By Region, 2022 - 2035 ($ Mn)
- 8.1 Key trends
- 8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
- 8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 France
- 8.3.4 Spain
- 8.3.5 Italy
- 8.3.6 Netherlands
- 8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 India
- 8.4.3 Japan
- 8.4.4 Australia
- 8.4.5 South Korea
- 8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Mexico
- 8.5.3 Argentina
- 8.6 Middle East and Africa
- 8.6.1 South Africa
- 8.6.2 Saudi Arabia
- 8.6.3 UAE
Chapter 9 Company Profiles
- 9.1 Abbott Laboratories
- 9.2 AgaMatrix
- 9.3 All Medicus
- 9.4 Arkray,
- 9.5 Ascensia Diabetes Care Holdings
- 9.6 B. Braun Melsungen
- 9.7 Bionime Corporation
- 9.8 DarioHealth Corporation
- 9.9 Dexcom
- 9.10 Essenlife Bioscience
- 9.11 F. Hoffmann-La Roche
- 9.12 LifeScan
- 9.13 Medtronic
- 9.14 Nova Biomedical
- 9.15 Sinocare
